BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17311621)

  • 1. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
    Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.
    McHutchison JG; Poynard T
    Semin Liver Dis; 1999; 19 Suppl 1():57-65. PubMed ID: 10349693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment.
    Malaguarnera M; Pistone G; Neri S; Romano M; Brogna A; Musumeci S
    BioDrugs; 2004; 18(6):407-13. PubMed ID: 15571424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
    J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.